Text Size

Mixed Chimeric Transplantation for Primary Amyloidosis

This study has been withdrawn prior to enrollment.
(Closed, never started.)
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186095
First received: September 13, 2005
Last updated: October 5, 2007
Last verified: October 2007
History of Changes
  Purpose

To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.


Condition Intervention
Amyloidosis
 Procedure: autologous followed by nonmyeloablative allogeneic transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Mixed Chimeric Transplantation for Primary Amyloidosis

Resource links provided by NLM:

MedlinePlus related topics: Amyloidosis
U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.

Secondary Outcome Measures:
  • Toxicity of therapy
  • Changes in marrow and serum abnormalities
  • Improvement in end-organ function.

Estimated Enrollment: 45
Study Start Date: December 2000
Estimated Study Completion Date: September 2006
  Eligibility

Ages Eligible for Study:   up to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • primary amyloidosis
  • adequate organ function
  • matched sibling donor

Exclusion Criteria:

  • evidence of multiple myeloma
  • HIV positive
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00186095

Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Keith Stockerl-Goldstein, MD Stanford University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00186095     History of Changes
Other Study ID Numbers: BMT129
Study First Received: September 13, 2005
Last Updated: October 5, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Stanford University:
Amyloidosis
nonmyeloablative
hematopoietic
cell transplantation

Additional relevant MeSH terms:
Amyloidosis
Proteostasis Deficiencies
Metabolic Diseases

ClinicalTrials.gov processed this record on June 18, 2013